Associate Dean for Clinical Affairs - Dubai Medical University - College of Pharmacy
Joined November 2013
- Tweets1.3K
- Following403
- Followers466
- Likes1.8K
Bassam Atallah, PharmD retweeted
نرتقي بمستقبل رعاية القلب والأوعية الدموية من خلال تبادل الخبرات وطرح رؤى جديدة.
اجتمع خبراء أمراض القلب والأوعية الدموية من مختلف أنحاء المنطقة في كليفلاند كلينك أبوظبي لحضور "المؤتمر الأول لتحديثات أمراض القلب والأوعية الدموية"، لتبادل الخبرات، واستكشاف أحدث التطورات في هذا المجال، إلى جانب تعزيز أساليب التعامل مع الحالات الطبية المعقدة.
Beyond SGLT2: The Emerging Role of Dual SGLT1/2 Inhibition in Heart Failure medscape.org/viewarticle/bey… via @MedscapeCME
Bassam Atallah, PharmD retweeted
An exciting new trial for #WNW - COBRRA compared apixaban vs rivaroxaban for VTE treatment and found a significantly decreased risk of bleeding associated with apixaban use (3.3% vs 7.1%); this RCT backs up the trend seen in retrospective data!
nejm.org/doi/10.1056/NEJMoa2…
Bassam Atallah, PharmD retweeted
Not noninferior = INFERIOR
Take your blood thinners folks - still the gold standard for stroke prevention in patients with AF who don’t have clear contraindication to anticoagulation.
Among patients with atrial fibrillation at high risk for stroke and bleeding, left atrial appendage closure was not noninferior to medical therapy in reducing the risk of stroke, embolism, major bleeding, or death at 3 years. Full CLOSURE-AF trial results: nejm.org/doi/full/10.1056/NE…
Editorial: Left Atrial Appendage Closure — Another Overused Method in Cardiology? nejm.org/doi/full/10.1056/NE…
ALT A graph of the primary end point
Bassam Atallah, PharmD retweeted
A messege from Dr Bassam Atallah:
"On #WorldPharmacistsDay, we recognize the crucial role pharmacists play in advancing safe, effective, and evidence-based cardiac care.
Thank you for your dedication to patients’ health."
#EmiratesCardiacSociety
#ECS @batallah08
Bassam Atallah, PharmD retweeted
ACC’s #FamilialHypercholesterolemia online course will keep you up to date on the latest tools & techniques to recognize HoFH & HeFH – a life-changing diagnosis that provides access to early treatment options. More ➡️ bit.ly/3vNLMqW
#ACCEd #CholesterolEducationMonth
Bassam Atallah, PharmD retweeted
ICYMI: A new ACC/AHA Scientific Statement introduces the PREVENT risk calculator & details the supporting evidence & rationale behind its use.
Learn more: bit.ly/41xhycz #hypertension @JACCJournals
Bassam Atallah, PharmD retweeted
New in JACC HF:
#Transferrin Saturation Is a Better Predictor Than Ferritin of Metabolic and Hemodynamic Exercise Responses in #HFpEF
shorturl.at/pknri
Bassam Atallah, PharmD retweeted
🫀 In familial hypercholesterolemia (HeFH), artery changes start young—carotid plaque at 17♂ / 30♀, coronary plaque at 26♂ / 36♀. Triple checks 🩻 (carotid, coronary, CAC) improve risk stratification & prevention 💪 Full study 👉 jacc.org/doi/10.1016/j.jacas… #JACCAsia #cvPrev
Bassam Atallah, PharmD retweeted
Finerenone reduced the need for loop diuretic dose intensification and lowered the average loop diuretic dose across all diuretic subgroups in patients with HFmrEF/HFpEF.
ja.ma/4meRfzV
Bassam Atallah, PharmD retweeted
AFIRE RCT: Rivaroxaban monotherapy yielded a consistent net clinical benefit across all age groups, especially in older patients with atrial fibrillation and stable coronary artery disease. ja.ma/3Jcoa9T
Bassam Atallah, PharmD retweeted
In frail, elderly #AFib patients previously on a vitamin K antagonist, switching to standard-dose direct-acting oral anticoagulant reduced stroke, fatal/intracranial bleeding, and death, despite more GI bleeding. jacc.org/doi/10.1016/j.jacc.… #JACC #DOAC
Bassam Atallah, PharmD retweeted
Kudos to @mfiuzat, @batallah08, Robert Page & Orly Vardeny for shedding light on the training, practice, & roles of HF pharmacists. jacc.org/doi/epdf/10.1016/j.…
Bassam Atallah, PharmD retweeted
🎤 Meet Dr. Bassam Atallah – Our Featured Speaker
Join Dr. Atallah (UAE) on July 23 as he walks us through pharmacologic innovations in HCM care—from classic medications to emerging myosin inhibitors.
With a decade of clinical and academic experience, Dr. Atallah brings a practical, evidence-based perspective.
📅 Don’t miss this live global session!
🔗 Free registration open now:
us06web.zoom.us/webinar/regi…
#ISCP2025 #CardioPharma #HeartHealth #MedicalWebinar
@doreen_sy
@ALorenzatti
@PabloAvanzas
@amartinezrubio
@KojiHasegawa6
@jckaski
@kjfilipiak
@beaverspharmd
@KarleziAlonso
@VebionaBachtar
@DanielPiskorz
@DrPontecarlosi
@santon74
@kit6750
@kfranco_c
@JD_Bennetts
@Risantilopezcar
@jacktanwc
The Current Landscape of Training, Practice, and Roles of Pharmacists ... sciencedirect.com/science/ar…
Bassam Atallah, PharmD retweeted
Original Article: Extended Reduced-Dose Apixaban for Cancer-Associated Venous Thromboembolism (API-CAT) nej.md/41YkRZK
Editorial: Cancer-Associated Venous Thromboembolism — Beyond 6 Months nej.md/4iB6wcA
#Cardiology
ALT A graph of the cumulative incidence of recurrent venous thromboembolism (primary efficacy outcome)
Bassam Atallah, PharmD retweeted
Congratulations to ACCP member Bassam Atallah and co-authors on the recent publication of their article in JACCP! Access the abstract and/or article here: ow.ly/1xGc50Vk7QC
@JACCPJournal #OpenAccess #MakingAnImpact #ACCP
